ArticleInflammopharmacology2025
Efficacy of Aster chinensis aerial parts metabolites in BALB/c mice model of Imiquimod-induced psoriasis skin inflammation.
Article in Inflammopharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Phytochemical profiling and multi-target pharmacological evaluation ofFrontiers in chemistry · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Using a bioassay-guided fractionation approach, the most potent anti-psoriatic components of Aster squamatus herb, Aster chinensis stalks, and Aster chinensis flowers, cultivated in Egypt, were identified and evaluated against Imiquimod (IMQ)-induced psoriasis in female BALB/c mice and compared to standard drug, mometasone. The topical application of A. chinensis stalk methanolic extract exhibited the strongest anti-psoriatic effects against IMQ-induced psoriasis model, as evidenced by improvements in psoriasis area severity index (PASI) score, histopathological analysis, and spleen index. Further fractionation of A. chinensis stalk methanolic extract using petroleum ether, methylene chloride, ethyl acetate, and n-butanol revealed that the methylene chloride fraction (MCF) was the most potent. Indeed, MCF significantly reduced the PASI score, alleviated histopathological changes, and restored spleen index. Mechanistically, MCF exerted its anti-psoriatic effects by suppressing inflammation, evidenced by decreased TLR-4 gene expression and lower levels of HMGB1 and NFκBp65 protein contents. Additionally, MCF reduced serum levels of pro-inflammatory cytokines interleukin (IL)-1β, IL-6, IL-23, and IL-17 while mitigating oxidative stress through increased superoxide dismutase (SOD) activity and reduced malondialdehyde (MDA) content. Notably, the efficacy of MCF was comparable to that of mometasone, with no significant differences observed. In parallel, the chemical profile of the MCF was analyzed using UHPLC-MS/MS techniques in negative and positive ionization full scan modes. MCF of A. chinensis stalk could be used a potential therapeutic agent for psoriasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.